首页 > 市场调查报告书 > 製药

呼吸器

全球肺病治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

市场调查报告书

商品编码

1346841

全球肺病治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

Global Lung Disease Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 242 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球肺病治疗市场需求预计将从 2022 年的 804.1 亿美元增至 2030 年的近 1164.1 亿美元，2023-2030 年研究期间复合年增长率为 4.7%。

肺部疾病治疗是指旨在管理和治疗各种肺部相关病症和疾病的医学治疗和干预措施。它涵盖影响呼吸系统的疾病，包括影响肺功能和整体呼吸系统健康的急性和慢性疾病。这些疗法可能涉及多种方法，包括药物、疗法、生活方式的改变，在某些情况下还包括手术干预。

市场动态：

在污染和人口老龄化等因素的推动下，肺部疾病的患病率不断上升，刺激了对有效治疗方法的需求。环境因素、技术进步和研究导致对治疗的需求不断增长。个性化医疗和新兴生物製药（例如靶向治疗）增强了治疗选择。不断增长的医疗保健支出、早期诊断意识和更严格的监管标准发挥了重要作用。 COVID-19 大流行凸显了呼吸系统健康的重要性并加速了该领域的研究。全球倡议、医疗保健基础设施发展和以患者为中心的方法进一步影响着市场。随着患者和医疗保健专业人员寻求改进的治疗方法，市场预计将不断发展。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球肺病治疗市场的每个细分市场进行了包容性评估。肺部疾病治疗行业的增长和趋势为这项研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲肺病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。肺病治疗市场的主要参与者包括葛兰素史克、阿斯利康、勃林格殷格翰、诺华、迈兰、Vertex Pharmaceuticals、F.Hoffam La Roche、Teva Pharmaceuticals、Cipla、Fibrogen、Liminal Biosciences、PharmAkea Therapeutics、IQVIA 。本节包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

区域展望
介绍
北美销售分析
- 概览、历史和预测数据销售分析
- 北美按细分市场销售分析
- 北美按国家/地区销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史和预测数据销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家/地区销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史和预测数据销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史和预测数据销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家/地区销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史和预测数据销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：肺病治疗公司的竞争格局

肺病治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
GSK

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Boehringer Ingelheim

公司简介
公司收入
产品
最近的发展

Novartis

公司简介
公司收入
产品
最近的发展

Mylan

公司简介
公司收入
产品
最近的发展

Vertex Pharmaceuticals

公司简介
公司收入
产品
最近的发展

F.Hoffam La Roche

公司简介
公司收入
产品
最近的发展

Teva Pharmaceuticals

公司简介
公司收入
产品
最近的发展

Cipla

公司简介
公司收入
产品
最近的发展

Fibrogen

公司简介
公司收入
产品
最近的发展

Liminal Biosciences

公司简介
公司收入
产品
最近的发展

PharmAkea Therapeutics

公司简介
公司收入
产品
最近的发展

IQVIA

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

简介目录图表

Product Code: VMR112112026

The global demand for Lung Disease Therapeutics Market is presumed to reach the market size of nearly USD 116.41 BN by 2030 from USD 80.41 BN in 2022 with a CAGR of 4.7% under the study period 2023 - 2030.

Lung disease therapeutics refers to the medical treatments and interventions aimed at managing and treating various lung-related disorders and diseases. It covers conditions affecting the respiratory system, including both acute and chronic diseases that impact lung function and overall respiratory health. These therapeutics can involve various approaches, including medications, therapies, changes in lifestyle, and, in some cases, surgical interventions.

MARKET DYNAMICS:

The increasing prevalence of lung diseases, driven by factors like pollution and ageing populations, fuels the demand for effective treatments. Environmental factors, technological advancements, and research contribute to the growing need for therapies. Personalized medicine and emerging biopharmaceuticals, such as targeted therapies, enhance treatment options. Rising healthcare expenditure, early diagnosis awareness, and stricter regulatory standards play significant roles. The COVID-19 pandemic highlighted respiratory health's importance and accelerated research in the field. Global initiatives, healthcare infrastructure development, and a patient-centric approach further influence the market. As patients and healthcare professionals seek improved therapies, the market is anticipated to evolve.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lung disease therapeutics. The growth and trends of lung disease therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the lung disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Lung Disease

By Drug Class

Corticosteroids
Bronchodilator Medications
Mucolytics
Antimicrobial Medications
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Lung Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lung Disease Therapeutics market include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F.Hoffam La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . LUNG DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

5.1 Overview by Disease Type
5.2 Historical and Forecast Data
5.3 Analysis by Disease Type
5.4 Asthma Historic and Forecast Sales by Regions
5.5 Chronic Obstructive Pulmonary Disease (COPD) Historic and Forecast Sales by Regions
5.6 Lung Cancer Historic and Forecast Sales by Regions
5.7 Other Lung Disease Historic and Forecast Sales by Regions

6 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Corticosteroids Historic and Forecast Sales by Regions
6.5 Bronchodilator Medications Historic and Forecast Sales by Regions
6.6 Mucolytics Historic and Forecast Sales by Regions
6.7 Antimicrobial Medications Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE LUNG DISEASE THERAPEUTICS COMPANIES

9.1. Lung Disease Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF LUNG DISEASE THERAPEUTICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. GSK
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AstraZeneca
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Boehringer Ingelheim
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Novartis
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Mylan
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Vertex Pharmaceuticals
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. F.Hoffam La Roche
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Teva Pharmaceuticals
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Cipla
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Fibrogen
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Liminal Biosciences
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. PharmAkea Therapeutics
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
10.15. IQVIA
- 10.15.1. Company Overview
- 10.15.2. Company Revenue
- 10.15.3. Products
- 10.15.4. Recent Developments